OBJECTIVE: The objective of this study was to compare the efficacy of two multi-agent chemotherapeutic regiments that were previously used at the Institution for treatment of advanced and recurrent endometrial cancer. METHODS: A retrospective review of patients with Stage III, IV, and recurrent endometrial cancer who received adjuvant chemotherapy at Roswell Park Cancer Institute over a period of 21 years. Two patient groups were defined based on treatment received: cisplatin, adriamycin, and VP-16 with or without megace (PAV-M), or carboplatin and paclitaxel (CT). RESULTS: Forty-two patients with advanced or recurrent endometrial cancer were included in this review based on regimen received. Median duration of follow up was 55 months. Treatment with PAV-M resulted in more dose modifications compared to CT group (42% vs 11%, respectively). There were no significant differences in disease-free survival or overall survival. CONCLUSIONS: PAV/PAV-M is active in patients with advanced or recurrent endometrial cancer. However, toxicity associated with this triplet regimen may limit clinical use.
OBJECTIVE: The objective of this study was to compare the efficacy of two multi-agent chemotherapeutic regiments that were previously used at the Institution for treatment of advanced and recurrent endometrial cancer. METHODS: A retrospective review of patients with Stage III, IV, and recurrent endometrial cancer who received adjuvant chemotherapy at Roswell Park Cancer Institute over a period of 21 years. Two patient groups were defined based on treatment received: cisplatin, adriamycin, and VP-16 with or without megace (PAV-M), or carboplatin and paclitaxel (CT). RESULTS: Forty-two patients with advanced or recurrent endometrial cancer were included in this review based on regimen received. Median duration of follow up was 55 months. Treatment with PAV-M resulted in more dose modifications compared to CT group (42% vs 11%, respectively). There were no significant differences in disease-free survival or overall survival. CONCLUSIONS:PAV/PAV-M is active in patients with advanced or recurrent endometrial cancer. However, toxicity associated with this triplet regimen may limit clinical use.
Authors: M J Piccart; G C Stuart; J Cassidy; K Bertelsen; M K Parmar; E A Eisenhauer; S B Kaye; C Tropé; K Swenerton; P Harper; J B Vermorken Journal: Ann Oncol Date: 1999 Impact factor: 32.976
Authors: Chad M Michener; Gertrude Peterson; Barbara Kulp; Kenneth D Webster; Maurie Markman Journal: J Cancer Res Clin Oncol Date: 2005-10-20 Impact factor: 4.553
Authors: Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen Journal: J Clin Oncol Date: 2003-07-14 Impact factor: 44.544
Authors: Charles W Whitney; Virginia L Brunetto; Richard J Zaino; Samuel S Lentz; Joel Sorosky; Deborah K Armstrong; Roger B Lee Journal: Gynecol Oncol Date: 2004-01 Impact factor: 5.482
Authors: Gini F Fleming; Virginia L Brunetto; David Cella; Katherine Y Look; Gary C Reid; Adnan R Munkarah; Richard Kline; Robert A Burger; Annekathryn Goodman; R Tucker Burks Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: Kyung Ae Ko; Yin Wang; Sivareddy Kotla; Yuka Fujii; Hang Thi Vu; Bhanu P Venkatesulu; Tamlyn N Thomas; Jan L Medina; Young Jin Gi; Megumi Hada; Jane Grande-Allen; Zarana S Patel; Sarah A Milgrom; Sunil Krishnan; Keigi Fujiwara; Jun-Ichi Abe Journal: Front Cardiovasc Med Date: 2018-04-05